oncolytic


Also found in: Dictionary, Medical, Wikipedia.

oncolytic

[‚äŋ·kə′lid·ik]
(medicine)
Pertaining to destruction of cancer cells.
References in periodicals archive ?
Entitled "Checkpoint Blockade Enhances Oncolytic Herpes Virotherapy in Immunosuppressive Sarcoma Models", this poster describes marked synergy between SEPREHVIR and an anti-PD-1 antibody in an immunocompetent, PD-L1 positive rhabdomyosarcoma model.
We aim to potentiate the antitumor immune reaction in the tumor microenvironment through the combination of immune therapy and oncolytic virotherapy.
This trial was conducted to evaluate single and repeated intratumoral injections of the oncolytic virus, HF10.
Shah and his team turned to mesenchymal stem cells (MSCs)-a type of stem cell that gives rise to bone marrow tissue-which have been very attractive drug delivery vehicles because they trigger a minimal immune response and can be utilized to carry oncolytic viruses.
he continued "So we loaded MSCs with oncolytic herpes virus and encapsulated these cells in biocompatible gels directly into the adjacent tissue after debulking.
A much smaller group of scientists have been working (much more quietly) on a more novel approach to cancer therapeutics called oncolytic viruses.
The research will come from the lab of John Bell, chief collaborator for oncolytic viral therapy at Jennerx Inc.
Oncolytics is focused on the development of oncolytic viruses as potential cancer therapeutics.
The logic in combining a replication-selective oncolytic virus with conventional chemotherapy and/or radiation is that these therapies work by very different mechanisms and their toxicities do not overlap.
GLASGOW, Scotland -- Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced the launch of the Virttu REPLICATE[TM] Open Innovation Forum.
5, 2015 /PRNewswire/ -- Virttu Biologics, a clinical stage oncolytic immunotherapeutic company developing SEPREHVIR, a tumor-targeted HSV, are pleased to announce the presentation of two posters at SITC's 30th Anniversary Annual Meeting on November 4th-8th.
AstraZeneca s global biologics research and development arm, MedImmune has inked a licensing agreement with Omnis Pharmaceuticals (Omnis) to merge key agents from its investigational immunotherapy portfolio with Omnis' lead investigational oncolytic virus programme, a genetically engineered strain of vesicular stomatitis virus (VSV).